Windtree Therapeutics Stock (NASDAQ: WINT)

Windtree Therapeutics (NASDAQ:WINT) Stock, Quote.Headers.trade-ideas

Windtree Therapeutics

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

Screenshot 2024-10-07 at 6.29.09 PM

Biotech

General

WINT

Windtree Therapeutics (NASDAQ: WINT) Announces Positive Phase 2b Results For Istaroxime In Early Cardiogenic Shock Treatment

News

Health Care

Movers

Windtree Therapeutics reports positive results from its Phase 2b study of istaroxime in patients with early cardiogenic shock, showing significant improvements in systolic blood pressure and a favorable safety profile.

Windtree Therapeutics Heart Failure Drug Candidate Improves Systolic Blood Pressure

movers image

Pre-Market Outlook

Markets

Trading Ideas

AGFY

EFSH

GLMD

HCTI

IOBT

ISPC

LUNR

MKDW

NEGG

OMEX

PRTG

SMSI

TNON

VEEA

VVPR

WATT

WBUY

XXII

Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics Inc

Windtree Therapeutics Inc arrants (25/03/2026)

WINTO GROUP HLDGS LTD by WINTO GROUP HLDGS LTD.

Wintrust Financial Corporation - Common Stock

Wintrust Financial Corp

Wintrust Financial Corporation - Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock, Series D

Wintrust Financial Corporation - Depositary Shares, Each Representing a 1/1,000th Interest in a Share of 6.875% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series E

Truist Securities analyst John McDonald maintains JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) with a Hold and raises the price target from $260 to $268.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on JPMorgan Chase, Raises Price Target to $268

Wells Fargo analyst Andrew Bauch maintains Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) with a Overweight and raises the price target from $85 to $95.

Wells Fargo Maintains Overweight on Block, Raises Price Target to $95

Webster Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>) will release earnings results for its fourth quarter, before the <a href="https://www.benzinga.com/quote/WBS/earnings">opening bell on Friday, Jan. 17, 2025.</a>
Analysts expect the Stamford, Connecticut-based company to report quarterly earnings at $1.35 per share, down from $1.46 per share in the year-ago period. Webster Financial projects to report revenue of $687.53 million for the recent quarter, compared to $634.84 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 18, 2024, Webster slashed its prime lending rate to 7.50%.
Webster Financial shares gained 3% to close at $58.16 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/WBS/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Barclays analyst Jared Shaw maintained an Overweight rating and raised the price target from $63 to $69 on Dec. 50, 2024. This analyst has an accuracy rate of 65%.</li>
<li>Wedbush analyst David Chiaverini maintained a Neutral rating and boosted the price target from $52 to $59 on Oct. 18, 2024. This analyst has an accuracy rate of 64%.</li>
<li>RBC Capital analyst Jon Arfstrom maintained an Outperform rating and raised the price target from $57 to $62 on Oct. 18, 2024. This analyst has an accuracy rate of 82%.</li>
<li>Morgan Stanley analyst Manan Gosalia maintained an Equal-Weight rating and cut the price target from $57 to $54 on Sept. 30, 2024. This analyst has an accuracy rate of 75%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Christopher Mcgratty maintained an Outperform rating and cut the price target from $58 to $55 on July 9, 2024. This analyst has an accuracy rate of 66%.</li>
</ul>
Considering buying WBS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16035549/image-102-1024x489.png" alt="" class="wp-image-736182" style="width:618px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16035549/image-102-1024x489.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16035549/image-102-300x143.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16035549/image-102-768x367.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16035549/image-102.png 1116w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42998360/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

Earnings

Webster Financial Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Wells Fargo analyst Andrew Bauch maintains BILL Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) with a Underweight and raises the price target from $55 to $65.

BILL

Wells Fargo Maintains Underweight on BILL Holdings, Raises Price Target to $65

Truist Securities analyst Jordan Levy maintains Generac Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) with a Buy and lowers the price target from $210 to $200.

GNRC

Truist Securities Maintains Buy on Generac Hldgs, Lowers Price Target to $200

Deep-pocketed investors have adopted a bearish approach towards Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SMCI usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 14 extraordinary options activities for Super Micro Computer. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 21% leaning bullish and 64% bearish. Among these notable options, 7 are puts, totaling $371,562, and 7 are calls, amounting to $391,801.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $27.0 to $40.0 for Super Micro Computer over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Super Micro Computer's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Super Micro Computer's significant trades, within a strike price range of $27.0 to $40.0, over the past month.
<h3>Super Micro Computer 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737038738_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$4.05</td>
<td>$3.9</td>
<td>$4.0</td>
<td>$30.00</td>
<td>$105.6K</td>
<td>124</td>
<td align="right">276</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$8.8</td>
<td>$8.6</td>
<td>$8.74</td>
<td>$30.00</td>
<td>$87.4K</td>
<td>1.5K</td>
<td align="right">103</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.45</td>
<td>$4.35</td>
<td>$4.35</td>
<td>$32.00</td>
<td>$86.9K</td>
<td>1.6K</td>
<td align="right">342</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$6.7</td>
<td>$6.45</td>
<td>$6.49</td>
<td>$31.00</td>
<td>$70.7K</td>
<td>1.0K</td>
<td align="right">132</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/24/25</td>
<td>$1.83</td>
<td>$1.67</td>
<td>$1.77</td>
<td>$32.00</td>
<td>$53.1K</td>
<td>677</td>
<td align="right">312</td>
</tr>
</tbody>
</table>

<h3>About Super Micro Computer</h3>
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data center, Big Data, high-performance computing, and "Internet of Things" embedded markets. Its solutions include server, storage, blade and workstations to full racks, networking devices, and server management software. The firm follows a modular architectural approach, which provides flexibility to deliver customized solutions. The Company operates in one operating segment that develops and provides high-performance server solutions based upon an innovative, modular and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.
After a thorough review of the options trading surrounding Super Micro Computer, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Super Micro Computer</h3>
<ul>
<li>With a volume of 1,497,830, the price of SMCI is up 3.34% at $32.02. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 11 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Super Micro Computer with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

SMCI

Market Whales and Their Recent Bets on SMCI Options

Wells Fargo analyst Andrew Bauch maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Overweight and raises the price target from $55 to $70.

AFRM

Wells Fargo Maintains Overweight on Affirm Holdings, Raises Price Target to $70

<a href="https://www.benzinga.com/personal-finance/24/07/39578712/charlie-munger-said-he-and-warren-buffett-always-self-insure-you-should-too-if-you-can-afford-it">Warren Buffett</a> has long credited insurance as the lifeblood of Berkshire Hathaway's empire, describing it as "the engine that has propelled our expansion since 1967," according to a 2016 CNBC article. And it's easy to see why.&nbsp;
With its unique financial structure and ability to generate a steady stream of investable capital, insurance has proved to be a critical driver of Berkshire's growth. But as natural disasters continue to increase in frequency and severity, the pressure on the industry – and its future profitability – has never been greater.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
</ul>
Buffett has never hidden his <a href="https://finance.yahoo.com/news/warren-buffett-says-insurance-business-140020919.html">enthusiasm for the insurance business</a>, often praising its up-front cash flow. "It's so much fun because you get the money at the start, you know and then you find out whether you've done something stupid later on," he said at the 2024 Berkshire Hathaway shareholders meeting. This quip perfectly captures the balancing act insurers face: collect premiums today and hope claims don't eat you alive tomorrow.
During that same shareholders meeting, he also stated, "Insurance is the most important business at Berkshire." But what makes the insurance model so appealing to Buffett isn't its immediate profitability – it's the float.&nbsp;
Float refers to the premiums insurers collect before they need to pay out claims. This pool of money is a financial gift that keeps on giving. Rather than sitting idle, it can be invested, generating returns for the insurer.&nbsp;
For Berkshire Hathaway, this float has been nothing short of transformative. Back in 1970, Berkshire's insurance float stood at a modest $39 million. By 2016, it had ballooned to $91.6 billion, providing Buffett with the fuel to fund acquisitions and investments that have turned Berkshire into its current conglomerate.
See Also: With 100+ historic trademarks including some of the high grossing characters in history, like Cinderella, Snow White and Peter Pan, <a href="https://www.benzinga.com/money/elf-labs-1">this company is transforming the $2 trillion entertainment market with patented AR, VR, and AI tech. — For a short window, investors are able to claim $2/share ($980 min).</a>
As Buffett put it in his 1997 shareholders letter, the formula is simple: "An insurance business has value if its cost of float over time is less than the cost the company would otherwise incur to obtain funds." In other words, so long as Berkshire's underwriting discipline keeps claim payouts manageable, the company can continue using its insurance float as a low-cost source of capital. And Berkshire has excelled here, maintaining an underwriting profit for 13 consecutive years – a rarity in an industry where operating at a loss is often the norm.
According to Reinsurance News, Berkshire insurance businesses generated a positive return of $5.4 billion for 2023.
Natural disasters have always been a risk, but they have become more frequent and severe over recent decades, driven by climate change and increased exposure in high-risk areas. The number of global natural disasters surged from 39 in 1960 to 396 in 2019, with extreme weather events like floods, hurricanes and wildfires becoming more common, according to Vision of Humanity.&nbsp;
Trending: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
Wildfires in California, <a href="https://www.benzinga.com/real-estate/24/12/42716127/slapping-lipstick-on-a-pig-investors-are-snatching-up-hurricane-damaged-homes-in-florida-to-flip-but-concerns-rise-over-repair-quality">hurricanes in Florida</a> and the Carolinas and other climate-related catastrophes put insurers in a tough spot. These disasters lead to massive claims, forcing companies to reevaluate risk models and hike premiums. While this may shore up the bottom line in the short term, it also raises critical questions about the long-term sustainability of insuring high-risk areas.
Buffett has acknowledged the competitive nature of insurance and its lack of traditional moats like patents or trademarks. "Insurance companies offer standardized policies which can be copied by anyone. Their only products are promises," he said. And yet, Berkshire's insurance subsidiaries – GEICO, General Re and others – have thrived by coupling disciplined underwriting with smart investments. Even in a crowded field, Berkshire's track record stands out.
Still, the stakes are higher than ever. As extreme weather events continue to strain insurers, companies must navigate a delicate balance: charging enough to cover rising risks without <a href="https://www.benzinga.com/personal-finance/24/04/38382525/suze-orman-decided-to-drop-homeowners-insurance-after-an-outrageous-quote-28-000-for-a-2-100-squ">pricing themselves out of the market</a>. For investors, Buffett's success in the sector offers lessons in patience, discipline and understanding the power of float. For insurers, it's a reminder that even the most profitable engines need careful tuning when the road ahead gets rough.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/advisor-adv-warren-buffett">Warren Buffett Flipped His Neighbor's $67,000 Life Savings Into A $50 Million Fortune — This Would Be Worth Over $500 Million Today</a></li>
<li><a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a></li>
</ul>

Personal Finance

Warren Buffett Says 'Insurance Is the Most Important Business' And The 'Engine' Driving Berkshire's Success Since 1967

Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) has outperformed the market over the past 5 years by 7.97% on an annualized basis producing an average annual return of 20.36%. Currently, Brown &amp; Brown has a market capitalization of $29.56 billion. 
Buying $100 In BRO: If an investor had bought $100 of BRO stock 5 years ago, it would be worth $252.55 today based on a price of $103.36 for BRO at the time of writing.
<h3>Brown &amp; Brown's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737038708_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Brown & Brown 5 Years Ago Would Be Worth Today

Wells Fargo analyst Gabe Hajde maintains Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) with a Equal-Weight and lowers the price target from $88 to $86.

Wells Fargo Maintains Equal-Weight on Crown Holdings, Lowers Price Target to $86

Truist Securities analyst Jordan Levy maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Buy and raises the price target from $400 to $420.

Truist Securities Maintains Buy on GE Vernova, Raises Price Target to $420

Israeli Prime Minister Benjamin Netanyahu has postponed a cabinet meeting that was set to vote on a ceasefire agreement with Hamas. The meeting has been delayed due to what Netanyahu has described as &#8220;last minute concession&#8221; <a href="https://www.benzinga.com/25/01/43011383/israel-gaza-ceasefire-hostage-exchange">demands from Hamas.</a>
What Happened: The vote, which was expected to take place on Thursday, has been put on hold by Netanyahu, who stated the meeting will only proceed once Hamas withdraws its demands. This development has cast doubt on the possibility of a ceasefire after 15 months of conflict, NPR <a href="https://www.npr.org/2025/01/16/nx-s1-5262339/israel-hamas-netanyahu-ceasefire">reports</a>.
Netanyahu stated the meeting will only proceed once mediators confirm all elements of the agreement have been fully accepted. He did not specify which parts of the deal Hamas had allegedly violated.
Senior Hamas official Sami Abu Zuhri has rejected Netanyahu&#8217;s claims, asserting that there is no foundation to the allegations that Hamas is backing out of parts of the ceasefire agreement.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43017610/oil-prices-break-80-reach-6-month-highs-despite-israel-hamas-ceasefire-deal-why-is-crude-rallying">Oil Prices Break $80, Reach 6-Month Highs Despite Israel-Hamas Ceasefire Deal: Why Is Crude Rallying?</a>
Netanyahu has been under pressure from right-wing members of his coalition government who oppose any form of deal with Hamas, according to NPR. These members have warned they may exit the coalition if a deal is finalized, a decision that could potentially topple Netanyahu&#8217;s government.
Why It Matters: The conflict between Isreal and Hamas has a long history, with the ceasefire agreement being a significant development. The verbal agreement for a ceasefire in Gaza was reached after months of negotiations and has the potential to bring an end to the ongoing war in the Middle East.
This development has had a significant impact on the stock market, <a href="https://www.benzinga.com/news/global/25/01/43013312/defense-stocks-fall-on-gaza-ceasefire-while-broader-market-rallies-whats-going-on">with defense stocks</a>, including Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) and Raytheon Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), experienced declines on Wednesday as news of a Gaza ceasefire gained traction.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/43019094/bidens-farewell-address-targets-tech-oligarchy-in-trump-2-0-era-president-says-americans-face-avalanche-of-misinformation">Biden&#8217;s Farewell Address Targets Tech Oligarchy In Trump 2.0 Era: President Says Americans Face &#8216;Avalanche Of Misinformation&#8217;</a></li>
</ul>
Photo: Shutterstock

Global

Netanyahu Postpones Ceasefire Vote, Raising Questions About Gaza Truce Prospects

Wells Fargo analyst Larry Biegelsen maintains Bausch &amp; Lomb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLCO#NYSE">BLCO</a>) with a Overweight and lowers the price target from $26 to $24.

BLCO

Wells Fargo Maintains Overweight on Bausch & Lomb, Lowers Price Target to $24

CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) shares are trading slightly lower by 0.4% to $51.91 during Thursday&#8217;s session. Shares of insurers and pharmacy benefit manager stocks are trading lower in possible reaction to UnitedHealth&#8217;s <a href="https://www.benzinga.com/general/health-care/25/01/43025159/unitedhealth-q4-earnings-revenue-falls-short-medical-ratio-rises-to-85-5-stock-falls">quarterly revenue miss</a>.
What To Know: Both UnitedHealth and CVS operate in overlapping sectors where investor sentiment often transfers. CVS, through its Caremark PBM and healthcare delivery services via Aetna, competes directly with UnitedHealth's Optum and UnitedHealthcare segments.
UnitedHealth&#8217;s <a href="https://www.benzinga.com/pressreleases/25/01/b43022980/unitedhealth-group-reports-2024-results">higher-than-expected</a> medical care ratio could signal rising costs and pressures that could affect CVS&#8217;s healthcare and insurance operations similarly, especially as both companies manage Medicare Advantage plans and navigate Medicaid redeterminations.
Additionally, UnitedHealth's missed revenue expectations might have heightened concerns about broader challenges in the healthcare industry, such as reimbursement rates, regulatory pressures or economic headwinds, which could also affect CVS. 
Investors may extrapolate UnitedHealth&#8217;s struggles to CVS, fearing similar financial or operational risks in a highly competitive market with narrow profit margins and cost-sensitive customers.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43027744/retail-sales-slow-jobless-claims-rise-is-us-consumer-loosing-steam">Retail Sales Disappoint, Jobless Claims Rise: Is US Consumer Losing Steam?</a>
<h2 class="wp-block-heading">How To Buy CVS Stock</h2>
By now you're likely curious about how to participate in the market for CVS Health &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of CVS Health, which is trading at $52.14 as of publishing time, $100 would buy you 1.92 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CVS has a 52-week high of $80.75 and a 52-week low of $43.56.

What's Going On With CVS Health Stock?

Wells Fargo analyst Whit Mayo maintains Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) with a Equal-Weight and raises the price target from $82 to $86.

Wells Fargo Maintains Equal-Weight on Bank of New York Mellon, Raises Price Target to $86

Wells Fargo analyst Elyse Greenspan maintains Prudential Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>) with a Equal-Weight and lowers the price target from $115 to $113.

Wells Fargo Maintains Equal-Weight on Prudential Financial, Lowers Price Target to $113

JMP Securities analyst Aaron Hecht maintains Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) with a Market Outperform and lowers the price target from $57 to $53.

JMP Securities Maintains Market Outperform on Caesars Entertainment, Lowers Price Target to $53

Truist Securities analyst Jamie Cook maintains Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) with a Buy and lowers the price target from $66 to $65.

Truist Securities Maintains Buy on Fluor, Lowers Price Target to $65

Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) announced Canadian pricing for its highly anticipated Lucid Gravity SUV.
The Lucid Gravity Touring will start at C$113,500 (~$78,900), while the Lucid Gravity Grand Touring will be priced at C$134,500.
Orders for the Grand Touring model, featuring 828 horsepower and a projected range exceeding 720 kilometers, will soon open for Canadian customers.
The Touring model will be added to the lineup in late 2025.
CEO Peter Rawlinson highlighted the strong anticipation for the Lucid Gravity in Canada, emphasizing its unique combination of performance, versatility, and design.
&#8220;This revolutionary vehicle is uniquely enabled through our technology and is perfectly suited to the demands of the Canadian market,&#8221; Rawlinson added.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/01/43019094/bidens-farewell-address-targets-tech-oligarchy-in-trump-2-0-era-president-says-americans-face-avalanche-of-misinformation" rel="noreferrer noopener">Biden&#8217;s Farewell Address Targets Tech Oligarchy In Trump 2.0 Era: President Says Americans Face &#8216;Avalanche Of Misinformation&#8217;</a>
The vehicle is tailored to meet the needs of the Canadian market, providing up to seven seats and a total of nearly 3,400 liters of usable cargo space.
The Lucid Gravity boasts Lucid&#8217;s advanced electric powertrain, offering outstanding efficiency with a 123kWh battery pack.
This technology ensures a smooth driving experience, with an optional three-chamber air suspension for improved handling on various terrains.
The Lucid Gravity will be on display at the Montreal International Auto Show from January 17 to 26, providing Canadian consumers with the first opportunity to experience the innovative SUV in person.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, LCID stock has gained over 5% in the past year. Investors can gain exposure to the stock via&nbsp;First Trust NASDAQ Clean Edge Green Energy Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCLN#NASDAQ">QCLN</a>).
Price Action: LCID shares are trading lower by 0.16% to $3.035 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/01/43013312/defense-stocks-fall-on-gaza-ceasefire-while-broader-market-rallies-whats-going-on" target="_blank" rel="noreferrer noopener">Defense Stocks Fall On Gaza Ceasefire While Broader Market Rallies: What&#8217;s Going On?</a></li>
</ul>
Photo via Company.

Equities

LCID

First Trust NASDAQ Clean Edge Green Energy Index Fund

QCLN

What's Going On With Lucid Group Stock Today?

BigBear.ai Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) shares are rising Thursday morning after the AI-powered decision intelligence company announced a <a href="https://www.benzinga.com/pressreleases/25/01/b43015538/kevin-mcaleenan-appointed-ceo-of-bigbear-ai">CEO transition</a>.
What To Know: BigBear.ai announced the appointment of&nbsp;Kevin McAleenan&nbsp;as CEO and a member of the company's board, effective Jan. 15. McAleenan has replaced&nbsp;Mandy Long, who is transitioning to an advisory role with the company.
Before the announcement, McAleenan was BigBear.ai's president. He previously served as Commissioner of U.S. Customs and Border Protection, where he focused on counterterrorism, border security and immigration enforcement. McAleenan also previously served as Acting Secretary of the U.S. Department of Homeland Security during President-elect&nbsp;Donald Trump's&nbsp;first administration.
&#8220;The demand for differentiated artificial intelligence solutions to provide strategic advantage in government and business is strong and the combination of recent technological achievements and strategic contract awards have positioned BigBear.ai as a leading AI solutions provider focused on national security imperatives,&#8221; said&nbsp;Peter Cannito, chair of BigBear.ai's board.
&#8220;Having served at the highest levels of government, Kevin brings an intimate understanding of current national security priorities and the challenges faced by our mission partners, providing BigBear.ai with a deep understanding of how artificial intelligence can be most effectively leveraged to maximize impact.&#8221;
BigBear.ai reported a 22.1% revenue increase in its most recent quarter, bringing in $41.5 million during the period. The company guided for full-year 2024 revenue of $165 million to $180 million. BigBear.ai is not due to report fourth-quarter results until early March. Analysts currently expect the company to report a loss of 4 cents per share and revenue of $54.48 million, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/43023453/quantum-computing-stocks-continue-their-wild-surge-in-thursday-premarket-qubt-up-15-qbts-climbs-9-rgti-gains-over-3">Quantum Computing Stocks Continue Their Wild Surge In Thursday Premarket: QUBT Up 15%, QBTS Climbs 9%, RGTI Gains Over 3%</a>
<h3 class="wp-block-heading">How To Buy BBAI Stock</h3>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in BigBear.ai's case, it&#8217;s in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
BBAI Price Action: <a href="http://benzinga.com/quote/bbai" target="_blank" rel="noreferrer noopener">BigBear.ai shares</a> were up 11.2% at $3.77 at the time of publication Thursday morning, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Shutterstock.

Management

BBAI

What's Going On With BigBear.AI Stock Thursday?

Windtree Therapeutics appoints new CEO

As of September 30, reported cash and cash equivalents of $2.3M and current liabilities of $14.4M, which includes an $8.6M warrant liability. The c...

Windtree Therapeutics reports Q3 EPS ($4.23) vs. ($15.47) last year

Windtree Therapeutics Inc ( ($WINT) ) has released its Q3 earnings. Here is a breakdown of the information Windtree Therapeutics Inc presented to i...

Windtree Therapeutics Reports Q3 2024 Financial Results

Windtree Therapeutics (WINT) announced that it has engaged New Growth Advisors, NGA, a leading life sciences consulting firm chosen by companies se...

Windtree Therapeutics announces partnership with New Growth Advisors

H.C. Wainwright analyst Vernon Bernardino reiterated a Hold rating on Windtree Therapeutics (WINT – Research Report) yesterday. The company's share...

H.C. Wainwright Sticks to Their Hold Rating for Windtree Therapeutics (WINT)

Windtree Therapeutics (WINT) announced that it has filed a new istaroxime PCT patent application entitled, "ISTAROXIME DERIVATIVES THEREOF FOR PREV...

Windtree Therapeutics announces new istaroxime patent filing

Windtree Therapeutics (WINT) announced that Alexandre Mebazaa, MD, one of the world's recognized leaders in cardiogenic shock, gave a presentation ...

Windtree Therapeutics announces presentation highlighting istaroxime

Windtree Therapeutics (WINT) has launched a new corporate strategy to become a revenue generating biotech company through acquisitions of small com...

Windtree lauches new corporate strategy to become revenue generating biotech

Windtree Therapeutics ( ($WINT) ) just unveiled an update. Windtree Therapeutics has appointed Leanne Kelly to its board of directors as an indepen...

Windtree Therapeutics Strengthens Leadership Amid Strategic Shift

Windtree Therapeutics (WINT) announced the issuance of a patent in Japan for "Inhibitors of atypical protein kinase C and their use in treating hed...

Windtree announces issuance of patent in Japan for oncology pipeline

Press Releases

Windtree Announces Leadership Transition Plan With Industry Veterans

Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction

Legal

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference

Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline

Comments

Windtree Therapeutics

Windtree Therapeutics (WINT) Forecast

Windtree Therapeutics (NASDAQ:WINT) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga